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family members’ health all increased significantly after COVID-19. Only a minority 
of African-Americans agreed they would get the needed healthcare if they contracted 
COVID-19. These findings have implications for the mental health and behavioral 
impacts of COVID-19 on African-Americans and for the development of health com-
munications to high-disease-incidence populations.
Disclosures:  All Authors: No reported disclosures
546. Capturing Clinician’s Experiences Repurposing Drugs to Inform Future 
Studies During COVID-19
Mili Duggal, MPH, PhD1; Heather Stone, MPH1; Parvesh Paul, MBBS, MD2; 
Reema Charles, MBBS, MS1; Leonard Sacks, MD1; Noel Southall, PhD2; 1FDA, Silver 
Spring, MD; 2NCATS/NIH, Silver Spring, Maryland
Session: P-21. COVID-19 Treatment
Background:  CURE ID is an internet-based repository developed collaboratively 
by FDA and NCATS/NIH, with the support of WHO and IDSA. It encourages clini-
cians globally to share novel uses of existing drugs for patients with difficult-to-treat 
infections. It is designed to serve as a rapid communication platform for healthcare 
providers during an outbreak, providing for systematic case-sharing, discussion, and 
the latest literature. Besides case reports, CURE ID offers a discussion platform for 
clinicians, disease-specific clinical trials curated from clincialtrials.gov, and a newsfeed 
that shows relevant journal articles and news related to COVID-19 and other infec-
tious diseases.
Methods:  The CURE ID team extracted individual case reports on patient-
level treatments and outcomes of COVID-19 infection from the published litera-
ture and gathered clinician-submitted cases through the electronic case report form. 
Additionally, CURE ID partnered with the University of Pennsylvania’s CORONA 
database to further populate the CURE ID database with published cases.
Results:  As of submission, lopinavir-Ritonavir (n=51) was the most commonly 
reported drug used. The following were also reported: hydroxychloroquine (n=31), 
azithromycin (n=28), arbidol (n=22), interferon alfa-2B (n=18), moxifloxacin (n=18), 
methylprednisolone (n=17), ivermectin (n=14), lopinavir (n=12), oseltamivir (n=12). 
The other drugs reported were danoprevir-ritonavir, intravenous immunoglobulins, 
interferon, interferon alfa, and tocilizumab. CURE ID currently includes more than 
150 detailed COVID case reports of 65 repurposed drugs. We expect case reporting 
for specific drugs to be dynamic and additional data to accrue. Updated results will 
be presented.
Conclusion:  Several drugs are being repurposed to treat COVID-19. CURE ID 
gives clinicians an opportunity to share their treatment experiences and discuss their 
questions with a global community of healthcare providers. By utilizing the CURE ID 
platform, in conjunction with data gathered from other registries, observational stud-
ies and clinical trials, hypotheses can be generated that may inform future clinical trials 
and ultimately, potentially find safe and effective treatments for this deadly disease.
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Background:  The SARS-CoV-2 pandemic has caused over 400,000 deaths 
worldwide thus far, and poses therapeutic challenges for millions of patients. There 
is currently no treatment for SARS-CoV-2 infection approved by the United States 
Food and Drug Administration. Multiple agents have been used off-label to treat 
SARS-CoV-2 infection based on small observational cohorts and in vitro data. Here 
we present the experience of a large academic medical center in treating SARS-
CoV-2 infection.
Methods:  We performed a retrospective cohort study of patients admitted for 
greater than 24 hours with a nasopharyngeal, oropharyngeal, and/or bronchoalve-
olar lavage sample positive for SARS-CoV-2 by polymerase chain reaction (PCR). 
Demographic data, comorbidities, clinical data, and treatment data were collected 
from the electronic medical record. Off-label therapies were used at the discretion of 
the treating providers guided by regularly updated treatment guidelines assembled by 
infectious diseases physicians and antimicrobial stewardship pharmacists. The primary 
outcome assessed was in-hospital mortality. Secondary outcomes included admission 
to the intensive care unit (ICU), endotracheal intubation, initiation of vasopressors, 
and drug-related adverse events.
Results:  Data collection was completed for 448 patients admitted between March 
18, 2020 and May 8, 2020. All-cause in-hospital mortality was 13.4% (60/448) during 
this time. Mortality rates increased with age, up to 45% for patients over 80 years old. 
Male sex, hypertension, chronic pulmonary disease, end-stage renal disease, chronic 
liver disease were also risk factors for increased mortality. QTc interval prolonga-
tion occurred significantly more frequently in patients who received hydroxychlo-
roquine (HCQ) with or without azithromycin(AZM) than those who did not (HCQ 
6%, HCQ+AZM 7.8% vs all other patients, 0%, p< .0001). Review of treatment trends 
showed close adherence to the treatment recommendations at that time (Figure 1).
Patient Characteristics
Admission Laboratory Data by Disease Severity
QTc Prolongation
Conclusion:  SARS-CoV-2 infection is associated with significant inpatient mor-
tality, and use of off-label treatments was associated with significant drug-related ad-
verse events. Treatment regimens changed rapidly, and providers adhered closely to 
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Treatment Trends by Week
QTC pre/post Treatment by Hydroxychloroquine Use vs. No 
Hydroxychloroquine Use
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Background:  Remdesivir (RDV) has been shown to shorten recovery time and 
was well tolerated in patients with severe COVID-19. Here we report baseline charac-
teristics associated with clinical improvement at day (d) 14.
Methods:  We enrolled hospitalized patients with confirmed SARS-CoV-2 infec-
tion, oxygen saturation >94% on room air, and radiological evidence of pneumonia. 
Patients were randomized 1:1:1 to receive 5d or 10d of intravenous RDV once daily 
plus standard of care (SoC), or SoC only. For this analysis, patients were followed 
through discharge, d14, or death. Baseline demographic and disease characteristics 
associated with clinical improvement in oxygen support (≥2-point improvement on a 
7-category ordinal scale ranging from discharge to death) were evaluated using multi-
variable logistic regression methods.
Results:  584 patients were randomized and treated (5/10d RDV, n=384; SoC: 
n=200). 159 (27%) were ≥65y, 227 (39%) female, 328 (61%) white, 102 (19%) Asian, 
and 99 (19%) Black. 252 participants (43%) were enrolled in Europe, 260 (45%) North 
America (NA), and 72 (12%) in Asia. Most patients (483 [83%]) were not on supple-
mental oxygen but required medical care at baseline. In a multivariable model, 5/10d 
RDV was significantly positively associated with clinical improvement (adjusted odds 
ratio [OR] 1.69, 95% CI: 1.08, 2.65; p=0.0226). Significant covariables positively asso-
ciated with clinical improvement included age < 65y (p< 0.0001) and region of treat-
ment (Europe and NA vs Asia, p< 0.0001 each; Table); other examined factors were not 
significantly associated with clinical improvement, including gender, race, ethnicity, 
baseline oxygen support, duration of symptoms and hospitalization, obesity, and base-
line transaminase levels.
Table 1.
Conclusion:  In moderate COVID-19 patients, after adjusting for treatment arm, 
age < 65y and region (NA vs Asia; Europe vs Asia) were associated with higher rates 
of clinical improvement. These observations recapitulate younger age as positive prog-
nostic factor, and highlight the differences in the impact of the pandemic globally.
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Background:  The Coronavirus disease of 2019 (COVID-19) global health crisis 
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted 
in unprecedented mortality, impacted society, and strained healthcare systems, yet 
sufficient data regarding treatment options are lacking. Convalescent plasma, used 
since 1895 for infectious disease outbreaks, offers promise as a treatment option for 
COVID-19.
Methods:  This is a retrospective study of patients diagnosed by a nasopharyn-
geal swab SARS-CoV-2 reverse transcriptase–polymerase chain reaction (RT-PCR), 
who received convalescent plasma between April to June 2020 at two large hospitals 
in Miami, Florida, as part of the US FDA Expanded Access Program for COVID-19 
convalescent plasma (CCP).
Results:  A total of 23 patients received CCP, 13 (57%) had severe COVID-19 dis-
ease, while 8 (35%) had critical or critical with multiorgan dysfunction. Median time of 
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